公开(公告)号：WO2009062050A2

公开(公告)日：2009-05-14

申请号：PCT/US2008082821

申请日：2008-11-07

Applicant: NEOGENIX ONCOLOGY INC ,  BRISTOL J ANDREW ,  KANTOR JUDITH A

Inventor： BRISTOL J ANDREW ,  KANTOR JUDITH A

IPC: C07K16/18 ,  C12N5/06 ,  C12N15/00 ,  C12N15/11

CPC classification number: C07K16/3046 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/6859 ,  A61K47/6863 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/57419 ,  G01N33/57438 ,  G01N33/577

Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

Abstract translation: 本发明提供结合人结肠直肠癌和胰腺癌相关抗原的重组单克隆抗体以及编码抗体链的核酸序列和对应于核酸的氨基酸序列，以及用于这些抗体，核酸和 氨基酸。

公开(公告)号：WO2016022723A1

公开(公告)日：2016-02-11

申请号：PCT/US2015/043867

申请日：2015-08-05

Applicant: MERRIMACK PHARMACEUTICALS, INC.

Inventor： GERETTI, Elena ,  MOYO, Victor ,  REYNOLDS, Joseph, G. ,  WICKHAM, Thomas

IPC: C07K16/32 ,  A61K47/48 ,  A61P35/00

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/704 ,  A61K45/06 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48615 ,  A61K47/48823 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6863 ,  A61K47/6913 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/55 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76

Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.

Abstract translation: 公开了用于治疗具有HER2阳性肿瘤的癌症患者（例如，耐药或不耐受百吗佐珠和阿曲曲妥单抗emtansine的癌症患者）的方法。 所述方法包括向患者施用治疗有效量的多柔比星负荷的免疫脂质体与靶向部分的组合，所述靶向部分是不是HER2信号传导的抑制剂的抗HER2抗体，以及包含不含阿霉素的抗癌治疗剂 包含不同抗HER2抗体的抗癌治疗剂。

公开(公告)号：WO2012082841A2

公开(公告)日：2012-06-21

申请号：PCT/US2011/064808

申请日：2011-12-14

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  DAVILA, Eduardo ,  TAMADA, Koji

Inventor： DAVILA, Eduardo ,  TAMADA, Koji

IPC: A61K39/395 ,  A61K31/4188 ,  A61P35/00

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K47/4813 ,  A61K47/48584 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/48746 ,  A61K47/555 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6897 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K2039/585 ,  C07K16/2863 ,  C07K16/44 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

Abstract translation: 本发明提供了一种通用但适应性强的抗标签嵌合抗原受体（AT-CAR）系统，其提供T细胞识别和杀死标记有标记抗体的靶细胞如肿瘤细胞的能力和特异性 。 作为示例，已经开发出表达FITC-CAR的T细胞，当这些细胞被癌反应性FITC标记的抗体结合时，T细胞特异性识别各种人类癌细胞。 显示表达FITC-CAR的T细胞的活化诱导有效的靶分解，T细胞增殖和细胞因子/趋化因子产生。 该系统可用于治疗患有癌症的受试者。

公开(公告)号：WO2017139623A1

公开(公告)日：2017-08-17

申请号：PCT/US2017/017435

申请日：2017-02-10

Applicant: IMMUNOMEDICS, INC.

Inventor： CHANG, Chien-Hsing ,  GOLDENBERG, David M.

IPC: A61K45/06 ,  A61K47/48 ,  C07K16/30

CPC classification number: C07K16/3061 ,  A61K31/4535 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/4985 ,  A61K39/3955 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48592 ,  A61K47/486 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48623 ,  A61K47/4863 ,  A61K47/48638 ,  A61K47/48684 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  A61K51/1057 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/3092 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.

Abstract translation: 本发明涉及包含附着于抗癌抗体或抗原结合抗体片段的药物的治疗性ADC。 优选药物是SN-38。 更优选地，抗体或其片段结合Trop-2并且该疗法用于治疗Trop-2阳性癌症。 最优选地，抗体是hRS7。 将ADC施用给患有癌症的受试者并结合ABCG2抑制剂。 联合治疗有效治疗单独对抗药物和/或单独对ADC有抗性的癌症。

公开(公告)号：WO2014020331A1

公开(公告)日：2014-02-06

申请号：PCT/GB2013/052036

申请日：2013-07-31

Applicant: OXFORD BIOTHERAPEUTICS LTD.

Inventor： ACKROYD, James Edward

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/3046 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48592 ,  A61K47/486 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6861 ,  A61K47/6863 ,  A61K51/1096 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/77 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2500/02

Abstract: The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer, for monitoring the effectiveness of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer treatment, and for drug development.

Abstract translation: 本公开提供了用于癌症的治疗，筛选，诊断和预后的方法和组合物，例如膀胱癌，食道癌，头颈癌，肺癌，胰腺癌，胃癌，子宫癌，子宫颈癌，皮肤癌和乳腺癌 用于监测癌症如膀胱癌，食管癌，头颈癌，肺癌，胰腺癌，胃癌，子宫癌，子宫颈癌，皮肤癌和乳腺癌治疗的有效性的癌症，以及药物开发。

公开(公告)号：WO2005113587A3

公开(公告)日：2006-05-18

申请号：PCT/EP2005005410

申请日：2005-05-18

Applicant: GANYMED PHARMACEUTICALS AG ,  TUERECI OEZLEM ,  SAHIN UGUR ,  KOSLOWSKI MICHAEL

Inventor： TUERECI OEZLEM ,  SAHIN UGUR ,  KOSLOWSKI MICHAEL

IPC: C07K14/47 ,  A61K39/395 ,  A61P35/00 ,  C07K14/705 ,  C07K16/30 ,  C12N9/88 ,  G01N33/574

CPC classification number: A61K6/00 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/6851 ,  A61K49/00 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3046 ,  C07K16/3076 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C12N9/88 ,  C12Y406/01002 ,  G01N33/57496

Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.

Abstract translation: 根据本发明，肿瘤相关基因产物表达，并识别编码它们的核酸。 本发明涉及一种其中这些肿瘤相关的基因产物被表达异常表达的疾病的治疗和诊断。 此外，本发明涉及表达肿瘤相关和核酸编码它们的蛋白质，多肽和肽。

公开(公告)号：WO2014126836A1

公开(公告)日：2014-08-21

申请号：PCT/US2014/015503

申请日：2014-02-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： CHENG, Heng ,  CONG, Qiang ,  GANGWAR, Sanjeev

IPC: A61K47/48 ,  C07K5/078 ,  A61P35/00

CPC classification number: C07K5/1024 ,  A61K38/05 ,  A61K38/07 ,  A61K47/48246 ,  A61K47/48415 ,  A61K47/48569 ,  A61K47/48592 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48638 ,  A61K47/6811 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6861 ,  A61K47/6863 ,  A61K47/6869 ,  C07K5/06 ,  C07K5/06139 ,  C07K5/06165 ,  C07K5/10 ,  C07K5/1016 ,  C07K7/06

Abstract: Tubulysin compounds of the formula (I) where R 1 , R 2 R 3a , R 3b , R 4 , R 5 , W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

Abstract translation: 其中R 1，R 2，R 3，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调节素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与靶向缀合时 部分。

公开(公告)号：WO2012082841A9

公开(公告)日：2012-08-09

申请号：PCT/US2011064808

申请日：2011-12-14

Applicant: UNIV MARYLAND ,  DAVILA EDUARDO ,  TAMADA KOJI

Inventor： DAVILA EDUARDO ,  TAMADA KOJI

IPC: A61K39/395 ,  A61K31/4188 ,  A61P35/00

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K47/4813 ,  A61K47/48584 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/48746 ,  A61K47/555 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6897 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K2039/585 ,  C07K16/2863 ,  C07K16/44 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

公开(公告)号：WO2009100194A2

公开(公告)日：2009-08-13

申请号：PCT/US2009033182

申请日：2009-02-05

Applicant: IMMUNOMEDICS INC ,  GOVINDAN SERENGULAM V ,  GOLDENBERG DAVID M ,  MOON SUNG-JU

Inventor： GOVINDAN SERENGULAM V ,  GOLDENBERG DAVID M ,  MOON SUNG-JU

IPC: C07K16/00 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

CPC classification number: A61K45/06 ,  A61K47/48215 ,  A61K47/48384 ,  A61K47/48523 ,  A61K47/4853 ,  A61K47/48561 ,  A61K47/48569 ,  A61K47/48584 ,  A61K47/48592 ,  A61K47/486 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48623 ,  A61K47/4863 ,  A61K47/48638 ,  A61K47/48715 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6839 ,  A61K47/6841 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6861 ,  A61K47/6863 ,  A61K47/6865 ,  A61K47/6867 ,  A61K47/6869 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/73

Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.

Abstract translation: 本发明涉及具有改善的靶向各种患有靶向部分（例如抗体或抗体片段），接头和喜树碱作为治疗部分的病变细胞的能力的治疗性缀合物，还涉及制备和使用所述缀合物的方法 。

公开(公告)号：WO2016209951A1

公开(公告)日：2016-12-29

申请号：PCT/US2016/038750

申请日：2016-06-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： ZHANG, Yong ,  BORZILLERI, Robert, M. ,  TEBBEN, Andrew, J. ,  STANG, Erik, M. ,  DONNELL, Andrew, F. ,  SCHROEDER, Gretchen, M. ,  PEREZ, Heidi, L. ,  WEI, Donna, D.

IPC: C07D519/00 ,  A61K31/5513 ,  A61K31/5517 ,  A61P35/00

CPC classification number: C07D498/22 ,  A61K31/5513 ,  A61K31/5517 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/48592 ,  A61K47/48615 ,  A61K47/48638 ,  A61K47/48715 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K47/6889 ,  C07D519/00 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3069

Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula (I) where A and B are independently according to formulae (Ia) or (Ib) ]; and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).

Abstract translation: 具有由式（I）表示的结构的大环苯并二氮杂二聚体，其中A和B独立地是根据式（Ia）或（Ib）]; 并且式（I），（Ia）和（Ib）中的其它变量如申请中所定义。 这种二聚体可用作抗癌剂，特别是用作抗体 - 药物偶联物（ADC）中的药物成分时。